Targeting deficiencies in the TLR5 mediated vaginal response to treat female recurrent urinary tract infection by Ali, Ased SM et al.
This is an author produced version of Targeting deficiencies in the TLR5 mediated vaginal 
response to treat female recurrent urinary tract infection.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/119009/
Article:
Ali, Ased SM, Mowbray, Catherine, Lanz, Marcelo et al. (12 more authors) (2017) Targeting
deficiencies in the TLR5 mediated vaginal response to treat female recurrent urinary tract 
infection. Scientific Reports. ISSN 2045-2322 (In Press) 
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
 1 
Targeting Deficiencies in the TLR5 Mediated Vaginal Response to Treat Female Recurrent 2 
Urinary Tract Infection. 3 
 4 
Authors: Ased SM Ali
1,2a
, Catherine Mowbray
1
,
 
Marcelo Lanz
1
, Anna Stanton
1
, Samantha Bowen
3
, 5 
Claire L Varley
4
, Paul Hilton
2
, Karen Brown
2
, Wendy Robson
2
, Jennifer Southgate
4
, Phillip Aldridge
1
, 6 
Alison Tyson-Capper
1
, Soman Abraham
3
, 
*
Robert S Pickard 
1,2*
,
 
Judith Hall
1*
, 7 
*Judith Hall and Robert S Pickard contributed equally to this work as senior supervising authors. 8 
Institutions:  9 
1. Institutes of Cell & Molecular Biosciences and Cellular Medicine, Newcastle University, UK 10 
2. Newcastle upon Tyne Hospitals NHS Trust, UK  11 
3. Duke University, NC, USA 12 
4. Jack Birch Unit, University of York, UK 13 
5. 
a
 Present address
 
Mid Yorkshire Hospitals, Aberford Rd, Wakefield, UK 14 
 15 
Corresponding Author: 16 
Dr Judith Hall, Institute for Cell & Molecular Biosciences, Faculty Medical Sciences, Newcastle 17 
University 18 
 19 
Telephone: +44 (0) 1912088346 20 
Email: Judith.Hall@ncl.ac.uk 21 
 22 
 23 
Summary:  The identification of the host defence peptides as target effectors in the innate defence of 24 
the uro-genital tract creates new translational possibilities for immunomodulatory therapies, 25 
specifically vaginal therapies to treat women suffering from rUTI, particularly those carrying the 26 
TLR5_C1174T SNP.   27 
 28 
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Urinary tract infections (UTIs) are a microbial disease reported worldwide. Women are particularly 39 
susceptible with many suffering debilitating recurrent (r) infections. Treatment is by antibiotics, but 40 
such therapy is linked to antibiotic resistance and re-infection. This study explored the innate 41 
protective mechanisms of the urogenital tract with the aim of boosting such defences therapeutically. 42 
Modelling UTIs in vitro, human vaginal and bladder epithelial cells were challenged with 43 
uropathogenic Escherichia coli (CFT073) and microbial PAMPs including flagellin, LPS and 44 
peptidoglycan. Flagellin functioning via the TLR5/NFκB pathway was identified as the key UPEC 45 
virulence factor causing a significant increase (P<0.05) in the production of the host-defence peptide 46 
(HDP), BD2. BD2-depleted urine samples from bladder infected mice supported increased UPEC 47 
growth, strengthening the significance of the HDPs in protecting the urogenital tissues from infection.  48 
Clinically, vaginal-douche BD2 concentrations were reduced (p<0.05) in women suffering rUTIs, 49 
compared to age-matched healthy controls with concentrations further decreased (p<0.05) in a 50 
TLR5
392Stop
 SNP rUTI subgroup. Topical vaginal estrogen treatment increased (p<0.001) BD2 51 
concentrations in all women, including those carrying the SNP. These data identify therapeutic and 52 
antibiotic sparing roles for vaginal immunomodulatory agents that specifically target HDP induction, 53 
facilitate bacterial killing and disrupt the UPEC infection cycle.   54 
 55 
Introduction 56 
Urinary tract infections (UTI), linked to Escherichia coli infecting the bladder are one of the most 57 
prevalent microbial diseases, accounting for over eight million health-care visits yearly in the United 58 
States 
1
. Females are particularly susceptible 
2
 and of those women affected 5%, rising to 13% in 59 
those aged over 60, 
3,4
 will suffer from debilitating recurrent infections (rUTI). These infections not only 60 
impact on a persons quality of life, but are also associated with escalating healthcare costs 
1
. In a 61 
number of cases the recurrent infections can be linked to an abnormality of the urinary tract 
5
, but a 62 
major characteristic of the disease is the poorly-defined relationship between the host 63 
genotype/phenotype and the main pathogen, uropathogenic E. coli (UPEC).   64 
In healthy individuals, the lower urinary tract is maintained free of pathogens through the functioning 65 
of host defences that include the pH and ionic composition of urine, which in conjunction with the 66 
flushing action of urine are detrimental to bacterial adherence and growth. Evidence also suggests 67 
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that these physical factors are supported by host innate, rather than adaptive, immune defence 68 
mechanisms with the high rates of UTI linked to the bladders inability to mount an antibody 69 
response
6
. Innate elements protecting the lower urinary tract include the activities of either 70 
constitutively or induced host defence molecules.  Antimicrobial agents such as uromodulin facilitate 71 
bacterial removal by binding UPEC directly, while others, including lactoferrin and neutrophil 72 
gelatinase-associated lipocalin-2, function by sequestering iron to restrict bacterial survival and 73 
growth
7
. Small cationic peptides, synthesised by epithelia and neutrophils, and including the 74 
defensins, cathelicidin, and ribonucleases, are also part of the urinary tract innate defences 
8
. These 75 
molecules, in addition to their intrinsic bacterial killing properties, fight infection through their 76 
immunomodulatory properties that promote increased cytokine production and neutrophil infiltration 
9
. 77 
However, the actual roles of such peptides in protecting the urogenital tract from infection remain 78 
contentious. Studies involving mice deficient in the antimicrobial peptides Defb1 (analogous to human 79 
Beta-Defensin-1) and cathelin-related antimicrobial peptide (analogous to the cathelicidin hCAP-18) 80 
report conflicting results, with the absence of peptides associated with either increased, reduced or no 81 
differences in UTI susceptibility 
10-13
.  82 
Epithelial cells recognise potential pathogens through receptors including the Toll-like receptors 83 
(TLRs). Once activated, the TLRs induce a rapid response that results in microbial killing either 84 
directly through the synthesis and activities of antimicrobial agents or indirectly through chemokines, 85 
and the attraction of neutrophils and macrophages.  Studies focussed on UPEC infection of the 86 
murine urinary tract suggest that TLR4 activation, linked to the detection of microbial 87 
lipopolysaccharide and/or FimH, the adhesin portion of the Type 1 fimbriae that secures UPEC 88 
attachment to urothelial cells, can trigger host innate antimicrobial defences 
14
. Following urothelial 89 
cell invasion, TLR4 is further implicated in the expulsion of UPEC and reinfection of the urinary tract, 90 
via an exocytic pathway linked to cellular cAMP 
15
. However, in vitro data using proliferating and 91 
differentiated normal urothelial cells favours TLR5 signalling mechanisms predominating in the human 92 
bladder 
16
. In support, murine studies have also demonstrated bacterial motility and TLR5 to be a key 93 
factors in UPEC pathogenicity, with wild-type flagellated UPEC shown to out-compete non-flagellated 94 
fliC mutants and maximum expression of flagellar genes coinciding with UPEC ascent into the ureters 95 
and kidneys 
17,18
. Clinically, patient susceptibility to UTI links to polymorphisms of both receptor genes 96 
with a TLR4_A896G polymorphism related to rUTI protection, but a TLR5_C1174T SNP linked to an 97 
increased susceptibility to repeated infections 
19,20
.  98 
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Current management strategies for rUTI sufferers are generally prophylactic involving long-term low 99 
dose antibiotics. In reality such strategies provide limited long-term benefit and encourage bacterial 100 
resistance that further complicates patient management. The treatment also conflicts with the current 101 
public health challenges of managing and reducing antibiotic overuse 
21,22
. Increasing concerns 102 
relating to the overuse of antibiotics has stimulated interest in alternative therapies including vaccine 103 
development and identification of agents able to boost endogenous innate defences of the urogenital 104 
tract 
8
. In females the initiating event of an UTI involves colonisation of the vaginal mucosa by UPEC 105 
originating, it is presumed, from the gut microbiota
23
, with UTI caused by the subsequent urethral 106 
migration and attachment of these bacteria to the urothelium 
24
.   107 
We show here that not only does deficiency in the vaginal host antimicrobial defences link to recurrent 108 
UTIs, but also that vaginal innate defences can be enhanced through topical immune boosting 109 
agents. We propose that such agents can be utilised to disrupt the UPEC infection cycle and hence 110 
offer an effective antibiotic-sparing approach to the treatment of rUTIs.   111 
 Results 112 
E.coli and Flagellin induce a TLR5-Mediated BD2 Response in Urogenital Epithelia 113 
Immortalised vaginal (VK2 E6/E7) and bladder cancer (RT4) cells modelling the urogenital epithelial 114 
tissues were challenged with a heat-inactivated suspension of the motile flagellated UPEC strain 115 
CFT073 and E.coli flagellin. Expression of genes DEFB1, DEFB4, DEFB103A, LCN2, SLPI, hCAP-18 116 
and DEF5A encoding the host defence molecules BD1, BD2, BD3, Lipocalin2, secretory leukocyte 117 
protease inhibitor (SLPI), cathelicidin and HD5 were assessed using end-point PCR. While these data 118 
suggested DEFB1 and DEFB4 gene expression to be upregulated (Fig 1a and Supplementary S1a-119 
d), qRT-PCR analyses identified only a significant increase in DEFB4 gene expression (Figs 1b & Fig 120 
S2) with these observations accompanied by a significant increase in BD2 peptide following CFT073 121 
(P<0.05) and flagellin (P<0.001) challenge (Fig 1c). These data were substantiated using primary 122 
human ureteric urothelial and vaginal epithelial cells (Fig 1d & e). Hence we selected BD2, an 123 
inducible bacterial killing molecule and immunomodulatory agent with reported potency in inhibiting 124 
UTI progression 
25
 as our key target in exploring and devising strategies to boost the UT innate 125 
defences.   126 
Challenging VK2 E6/E7 and RT4 cells with flagellated (motile) and non-flagellated (non-motile) 127 
Escherichia coli indicated that the signalling mechanism controlling BD2 production in the urogenital 128 
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tissues was TLR5 mediated and linked to flagellin (Fig 1f). This was further indicated by a reduction in 129 
DEFB4 transcript expression in flagellin challenged vaginal VK2 E6/E7 cells following siRNA silencing 130 
of TLR5 gene expression (Fig 1g). In support decreased BD2 concentrations were also detected in 131 
the media bathing the vaginal cells similarly challenged with flagellin, but in which TLR5 had been 132 
blocked using antibody (Fig 1h). The use of RT4 bladder cells engineered to contain a NFκB-133 
luciferase reporter also indicated the NFκB signalling pathway to be involved with a four hour flagellin 134 
challenge linked to a significant 44.8 fold increase in luciferase activity (P<0.001) (Fig 1i). In 135 
comparison only slight induction of NFκB activity was observed at four hours following either 136 
peptidoglycan (3.1 fold) or lipopolysaccharide (LPS) challenges (6.7 fold) with maximal responses at 137 
16 hours of 6.2 and 10.7 fold respectively (Fig 1i). However, LPS challenges of up to 24 hours in vitro 138 
did not induce DEFB4 expression (FigS3). These data identified TLR5/NFκB/BD2 as a key signalling 139 
pathway in the innate response of the urogenital epithelia to a flagellated UPEC infection. 140 
Deficiency of BD2 Orthologue (DefB4) in Mice Increases Susceptibility to UTI 141 
To verify this pathway and the significance of host defence peptides including BD2 in vivo, C57BL/6J 142 
WT and Tlr5-/- knockout mice bladders were inoculated with either buffer (PBS), E.coli derived flagellin 143 
(5µg) or CFT073 (10
8
) and the murine bladder and vaginal tissues examined for DefB4 gene 144 
expression. The DefB4 gene is the mouse orthologue of the human DEFB4 gene 26. C57BL/6J WT 145 
mice showed a significant increase in bladder DefB4 transcript expression (P<0.05) in response to the 146 
flagellin challenge (Fig 2a), while significant changes in both bladder and vaginal expression (P<0.05) 147 
were associated with the bacterial (CFT073) infection (Fig 2a, b). No renal DefB4 transcript 148 
expression was identified (data not shown) and no bacteria were recovered from the kidneys (Fig 2c).  149 
The bladder and vaginal tissues of similarly challenged Tlr5-/- mice showed no significant induction of 150 
DefB4 transcript expression (Fig 2a, b).  At six hours post challenge the bladder bacterial counts of 151 
these mice were also significantly higher than those recorded in the C57BL/6J WT mice (Fig 2c). 152 
Additionally bacteria were recovered from the kidneys of the Tlr5-/- mice indicating the increased 153 
susceptibility of their urinary tracts to an ascending UTI (Fig 2c). These in vivo data supported the 154 
significance of the urogenital epithelial TLR5/BD2 host defence peptide (HDP) signalling response in 155 
the immediate protection of the lower and upper urinary tract from UPEC infection. 156 
 157 
 158 
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Biological Relevance of BD2 in the Innate Response of the Uro-genital Tract 159 
To address the biological relevance of host defence peptides in the innate defence of the urogenital 160 
tissues the antimicrobial potencies of an array of agents including BD2, LCN and SLPI (7.5 to 250 161 
nM) were compared using a time-kill assay approach and CFT073 as the target bacterium.  Using 162 
peptide concentrations mimicking those at the epithelial surface
27,28
 these assay data suggested the 163 
induced BD2 peptide to possess significant antimicrobial potency against the CFT073 strain (Fig 3a).  164 
Immuno-depletion of BD2 from the wild-type mouse urine samples collected following challenge with 165 
CFT073 and flagellin was also associated with increased CFT073 growth (Fig 3b). These data 166 
provided direct evidence that a urogenital deficiency of host defence peptide links to the increased 167 
risk of UTI.    168 
Women with rUTI and TLR5_C1174T SNP show Reduced BD2  169 
To examine the clinical significance of host defence peptides in defending against rUTIs we focused 170 
on DEF4B expression and BD2 synthesis in vaginal biopsies, vaginal secretions (douche) and urine 171 
samples from 86 women. Forty-eight women had a history of rUTIs, including 14 with a symptomatic 172 
E.coli infection at time of sampling and 38 were age-matched controls. Analyses of the vaginal 173 
biopsies indicated that those women suffering rUTIs showed significantly lower DEF4B transcript 174 
expression (p<0.05) compared to their respective controls (Fig 4a). The vaginal douche 175 
measurements also supported these data with the mean BD2 concentration being significantly 176 
reduced (P<0.05) in the rUTI cohort (25.3±3.2 pg/ml) compared to the control group (38.9±5.5 pg/ml) 177 
(Fig 4b). Stratification of these vaginal douche data also showed that the mean BD2 concentrations of 178 
the pre and postmenopausal rUTI cohorts were significantly decreased (p<0.05) compared to their 179 
respective controls (Fig 4c). Furthermore, the mean BD2 concentration of the postmenopausal rUTI 180 
group was significantly decreased (p<0.001) compared to that of the premenopausal rUTI cohort.  181 
TLR5 gene expression data suggested no significant differences between vaginal expression in the 182 
control and rUTI cohorts, and expression was elevated significantly (P<0.05) during active infections 183 
(Fig 4d). These data suggested that the observed reductions in BD2 were related to cellular signalling 184 
events linked to and/or downstream of TLR5. To explore this further we sequenced the TLR5 genes 185 
of the patient and control cohorts. Sequencing identified a sub-group of six women (7%), all contained 186 
within the rUTI group, who carried the TLR5_C1174T single nucleotide polymorphism (SNP). Also 187 
known as TLR5
392Stop
, this polymorphism is a heterozygous variant present in 5-10% of the population 188 
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encoding a stop-codon, which is reported to increase the susceptibility of those affected to flagellated 189 
infections 
29,30
. Vaginal douche measurements also supported HDP concentrations being significantly 190 
lower (P<0.01) in this group compared to the no SNP rUTI cohort (Fig 4b).  191 
Of the fourteen women with an active UTI during our sample collections, nine carried the wild-type 192 
TLR5 gene and five the TLR5
392Stop
 SNP. Analyses of urines and vaginal washings of these women 193 
during their active infections showed that the SNP cohort had significantly lower mean BD2 194 
concentrations in both urine (P<0.05) and vaginal douche (P<0.001) samples compared to those of 195 
the no SNP group (Fig 4e). Furthermore, analysing the urine BD2 concentrations of the TLR5
392Stop
 196 
SNP cohort during periods of infection and quiescence showed no significant differences (Fig 4f), 197 
confirming the inability of the urogenital tissues of these SNP patients to respond to infection. In 198 
contrast the urine BD2 concentrations of the no SNP rUTI patients were elevated (P<0.01) in 199 
response to infection (Fig 4f). However, further analyses showed that the BD2 concentrations of the 200 
no SNP rUTI patients measured during an active UTI were actually very similar to those of the control 201 
pre-menopausal group (Fig 4g). These data suggested that the vaginal BD2 responses in the no SNP 202 
rUTI patients were considerably compromised, which increased their susceptibility to recurrent 203 
infections. The diminished host BD2 response of the no SNP rUTI group implicated host signalling 204 
defects linked to and/or downstream of TLR5.   205 
To demonstrate that the rUTIs suffered by the SNP patients were due to host-susceptibility rather 206 
than bacterial virulence factors, E.coli were isolated from the urine samples of three of the SNP 207 
patients and used to challenge the stably transfected RT4-NFκB luciferase reporter cells. Significant 208 
increases in NFκB-reporter activity comparable to flagellin (250ng/ml) were recorded following 209 
challenges with each of the UPEC strains (Fig 4h). These data verified that the genetic TLR5
392Stop
 210 
polymorphism played a key role in predisposing these women to repeated UTIs. Modelling the 211 
polymorphism experimentally by TLR5 antibody blocking of the RT4-NFκB luciferase reporter cells, 212 
prior to bacterial challenges, reduced NFκB reporter activity (Fig 4i) and diminished the epithelial 213 
effector IL-8 and BD2 responses (Fig 4j, k). Consistent with the bladder response (Fig 4k) and 214 
patient data a reduction in BD2 was observed in similarly challenged vaginal cells (Fig 4S).   These 215 
data provided further evidence that in the urogenital tract the epithelial host TLR5-NFκB-HDP 216 
signalling pathway functions in helping to protect from UTIs and if compromised, the loss of such 217 
defences, can expose the tissues to infection.   218 
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Deficient BD2 Responses can be Enhanced Therapeutically In Vitro and Clinically 219 
For all rUTI patients, including those carrying the TLR5 SNP, topical agents that boost the urogenital 220 
defences, including BD2 synthesis, may provide additional and/or alternative therapies to antibiotics. 221 
Vaginal estrogen supplements can be used to reduce UTI risk in post-menopausal women suffering 222 
rUTIs, but the mechanisms of action are not fully understood 
31-33
. When VK2 E6/E7 vaginal cells 223 
were supplemented with 4nM estrogen for 7 days and then challenged with flagellin (50ng/ml) DEF4B 224 
transcript expression and BD2 synthesis were significantly (P<0.01) potentiated (Fig 5a, b). These in 225 
vitro data suggest that the steroid hormone, in addition to its roles in reproduction, functions in 226 
augmenting the innate immune defences of the urogenital tract.  When examined clinically, the 227 
vaginal BD2 concentrations of post-menopausal women suffering rUTIs, but prescribed topical vaginal 228 
estrogen (Vagifem 10mcg twice weekly), for a minimum of six weeks were significantly increased 229 
(P<0.001), compared to those treated using other therapies including antibiotic prophylaxis and/or 230 
advice (Fig 5c, d). These vaginal douche data were supported by vaginal biopsies taken from 231 
estrogen-treated women that showed immunoreactivity for BD2 (Fig 5e). Together these data provide 232 
compelling evidence that estrogen can enhance the host vaginal epithelial defences through the 233 
increased synthesis of host defence molecules and help protect from rUTIs. The fact that the BD2 234 
vaginal douche concentrations of the rUTI TLR5 SNP patients were augmented in response to topical 235 
vaginal estrogen treatment (Fig 5f), lends support to the use of immune-boosting vaginal therapies to 236 
help treat rUTIs.    237 
We propose therefore that the TLR5-NFκB-host defence effector pathway is a significant innate 238 
defence mechanism helping to protect the urogenital tract against rUTI. We propose that for women 239 
carrying the TLR5 SNP and hence genetically predisposed to rUTI, as well as post-menopausal 240 
women, this pathway be exploited clinically. We argue that the use of topical immune modulating 241 
therapies that activate and/or enhance the vaginal innate defences will help prevent bacterial 242 
colonisation and ascension into the urinary tract (Fig 5g).  243 
Discussion 244 
UTI is one of the most prevalent microbial diseases worldwide. It is characterised by high recurrence 245 
rates amongst sufferers and by the marked, and increasing multi-drug resistance profiles of 246 
uropathogenic bacteria, a consequence of the mainstay therapy being limited to repeated or 247 
prophylactic antibiotic treatments 
34,35
.  Key challenges to science and medicine are to reduce 248 
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recurrence rates and improve patient outcomes through new therapeutic options that curtail antibiotic 249 
usage.  250 
To address this our studies focussed on both bacterial virulence factors and the host urogenital 251 
defences. In support of previous reports
16,18
 our in vitro and murine data indicated that flagellated 252 
E.coli through TLR5 activation play a key role in the pathology of UTI. These data were further 253 
strengthened by our clinical findings, which showed that all patients carrying the TLR5_C1174T SNP, 254 
encoding a stop mutation linked to increased susceptibility to flagellated bacteria
20
, suffered from 255 
recurrent UTIs. The fact that the in vitro, murine and clinical study data were all characterised by the 256 
reduced production of host defence molecules, including bacterial killing peptides and chemokines, 257 
provided a mechanistic explanation to link a TLR5 deficiency to repeated infections of the bladder.  258 
Furthermore this immunodeficiency impacted similarly on the TLR5 signalling pathway of the vaginal 259 
tissues. In view of this we propose that the resultant reduction in innate effector molecules facilitates 260 
the repeated colonisation of the vaginal mucosa by gut E. coli, which drives the persistent bladder 261 
infections. This mechanism also explains why antibiotic therapy can never cure women carrying the 262 
TLR5
392Stop
 SNP and in fact why repeated treatments only exacerbate the condition through selecting 263 
for antibiotic resistance.  Hence as a first step we propose that women suffering uncomplicated rUTI 264 
should be tested for the SNP to further inform their clinical management.   However, herein lies the 265 
next problem as there are few clinical alternatives to treating rUTIs other than advice and antibiotics.  266 
Topical estrogen treatment is an option in reducing UPEC colonisation of the vaginal tissues and 267 
helping to protect against repeated infections. Our clinical data, which showed elevated vaginal BD2 268 
concentrations in patients prescribed estrogen treatment corroborated a previous report where 269 
estrogen therapy enhanced the bladder innate response and strengthened the integrity of the 270 
urothelium 
32
.  Our premise that estrogen functions synergistically to boost the urogenital innate 271 
defences was further supported by our observation of a significant reduction in the urine and vaginal 272 
douche BD2 concentrations of postmenopausal patients suffering rUTI, but carrying wild-type TLR5. 273 
The report that vaginal estrogen is also associated with increased Lactobacilli growth, which impacts 274 
on the survivability of uropathogens 
36
, further supports its use as a rUTI therapy. Yet, despite its 275 
potential, vaginal estrogen is clinically acceptable only in post-menopausal women and due to 276 
concerns including endometrial hyperplasis
37
 is only recommended for limited periods. However, 277 
other potential agents for therapeutic consideration-include hyaluronic acid and chondroitin sulphate, 278 
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whose intravesical use have been linked to decreased UTI recurrence and  in vitro to host defence 279 
peptide stimulation, including increased defensin synthesis 
38-40
.  280 
Our vaginal therapy option to help treat rUTI sufferers carrying the TLR5 SNP (Fig 5g) is based on the 281 
premise that recurrence links to infections that are propagated through bacteria originating in the gut-282 
faecal material ascending the urethra into the bladder
23,41,42
. However, recurrent infections can also be 283 
explained using the intracellular bacterial community/quiescent intracellular reservoir (IBC/QIR) model 284 
established through studies in mice
43
. This model relies on UPEC ascending the urethra, invading the 285 
bladder epithelium and forming either IBCs that contain metabolically-active bacteria capable of 286 
infecting adjacent cells or non-replicating quiescent intracellular reservoirs. Following a stimulus, 287 
possibly months after the initial infection and potentially involving urothelial turnover involving actin 288 
rearrangements, these latent bacteria emerge to initiate a new acute infection. However, while the 289 
IBC/QIR model has been demonstrated in multiple mouse backgrounds
44
 there is limited evidence to 290 
support its functioning in humans
45,46
. Furthermore, the infection model does not fit well with data that 291 
links vaginal treatments to reduced UTI incidence
31,33
 292 
The answer to developing rUTI therapies applicable for all groups of women lies in understanding the 293 
disease pathology in relation to both the host response and bacterial virulence. To date, studies 294 
investigating UTIs and potential new UTI treatments have focussed largely on the virulence factors 295 
used by uropathogens at the primary site of infection, the bladder 
43
.  While such information is not 296 
generally taken into account in clinical decisions involving antibiotics, it has informed potential 297 
treatment strategies including vaccination.  However, the use of vaccines to treat rUTIs remains 298 
tentative with whole pili immunogens proving ineffective and other methods focussed on UPEC toxins, 299 
siderophores and the FimC-FimH complex, either providing no protection or reducing, but not totally 300 
inhibiting bladder colonisation  
47,48
. Oral therapeutics called mannosides, which function as FimH 301 
anatagonists and reduce bacterial attachment at the bladder tissues show strong potential with the 302 
efficacy of a new class, the C-mannosides, demonstrated in vivo using animal models of UTI 49,50. 303 
Recently the FimH antagonist M4284 has been shown to reduce UPEC colonisation of the mouse gut 304 
without impacting on the gut microbiota, and hence if developed therapeutically, could reduce UTIs 305 
and rUTIs
51
. Deliberately establishing asymptomatic bacteruria in UTI-prone patients through the use 306 
of non-adhering E.coli, has also been reported to be relatively successful in reducing UTI episodes 52.  307 
However, from our knowledge and understanding of the host innate defences we also advocate the 308 
development and use of topical vaginal treatments that function, either by mimicking the action of 309 
11 
 
estrogen or through novel signalling pathways, to boost the endogenous innate defences of the 310 
vaginal tissues and reduce vaginal E.coli colonisation (Fig 5g). We propose that such treatments, by 311 
interrupting the UPEC infection cycle, will offer an additional, but simple antibiotic-sparing therapeutic 312 
approach to the treatment of patients suffering rUTIs including those carrying the TLR5
392Stop
 SNP.   313 
 314 
 315 
Methods 316 
Cell Culture  317 
The RT4 urothelial cell line (ATCC HTB-2) 
53
 was maintained without antibiotics in 25mM HEPES (4-318 
[2-hydroxyethyl]-1-piperazineethanesulfonic acid) modified RPMI 1640 medium supplemented with 2 319 
mM glutamine and 10% fetal bovine serum (Sigma, Dorset, UK).  VK2 E6/E7 cells (ATCC CRL-2616) 320 
54
 were maintained without antibiotics in keratinocyte serum-free medium (GIBCO, Paisley, UK) 321 
containing 0.4mM calcium with 0.1 ng/ml human recombinant Epidermal Growth Factor (EGF) and 322 
0.05 mg/ml bovine pituitary extract supplements. Normal human urothelial cells were isolated, 323 
expanded and maintained in culture as previously described 
55
. 324 
Cell Challenge Studies 325 
RT4 and VK2 E6/E7 cells were seeded at 10
4
 cells/well into 30 mm, six well plates and cultured to 326 
confluency at 37ºC in 5% CO2.  Prior to challenge, cell monolayers were washed in phosphate 327 
buffered saline (PBS) and incubated for 24h in fresh medium.  328 
NU14
56
 , NCTC 10418 (ATCC 10536), K12
57
 and CFT073 
58
 bacterial cultures were tested for motility 329 
as described previously 
59
.  Bacterial cultures were prepared for use in cell challenge experiments as 330 
follows: Fifty µl of a 5ml log phase culture was used to inoculate a further 5 ml of medium and cultured 331 
again to log-phase (3 h). Twenty ȝl of this culture was re-suspended in 980 ȝl PBS to give a working 332 
suspension and 20 ȝl of this (approximately 5x104 colony forming units (CFU)) used to inoculate each 333 
well of eukaryote cells for the time required. Dead bacteria were produced by incubating live bacterial 334 
stock solution for 30 minutes at 65 ºC and confirmed by overnight agar plating. For bacterial 335 
component challenges, each well of eukaryote cells was inoculated with 20 ȝL of either LPS, 336 
Peptidoglycan (Invivogen, San Diego, California, USA) or E. coli flagellin60. For BD2 enhancement 337 
studies cells were supplemented with 4nM cyclodextrin encapsulated 17ȕ-oestradiol dissolved in 338 
water (Sigma) or 15nM (2-hydroxypropyl)-ȕ-cyclodextrin for up to seven days prior to challenge. Once 339 
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the cells reached 80% confluency the cell culture medium was removed, the cells were washed with 340 
PBS and incubated a further 24 hours in medium supplemented with 15nM cyclodextrin only. At each 341 
appropriate challenge time points the medium was removed from the wells and stored at -20
o
C for 342 
ELISA and the cells subjected to RNA extraction.  343 
The time-kill antimicrobial assays using recombinant peptides, BD2 (Preprotech), LCN2 (Biovision),  344 
and SLPI (RD systems) were adapted from the technique used previously 
61
. 345 
NFțB Reporter Measurements 346 
RT4 cells stably transfected with a NFκB luciferase reporter 
62
  and maintained under G418 selection 347 
(Sigma, UK) at 0.5mg/ml were seeded onto 30 mm diameter, six well plates at a density of 10
5 
348 
cells/well and cultured until 90% confluent. Following challenge with either PBS, bacteria or bacterial 349 
components, the cells were lysed in RLB (Promega, Southampton, UK) for 16 hours at -80 
o
C and 350 
following the addition of luciferin (Promega), luminescence was measured using a FluoStar Omega 351 
microplate reader (BMG Labtech, Ortenberg, Germany). The results were presented as fold increase 352 
over the control PBS challenge.  353 
Activation of TLR-5 was inhibited by incubating cells with up to 5 ȝg/ml of mouse monoclonal TLR-5 354 
antibody (maba2-htlr5, Invivogen, San Diego, USA) or IgG (5µg/ml) 2 hours prior to bacterial or 355 
flagellin challenge.  356 
End-point, Quantitative RT-PCR and siRNA analyses 357 
Extraction of RNA from either cultured cells or the human tissue samples was performed using 358 
TRIzol® reagent following the manufacturers instructions (Invitrogen) and all RNA samples were 359 
stored in RNAsin
TM
 (Promega) at -80 °C.  cDNA preparation and transcript abundance, measured by 360 
either end-point or quantitative RT-PCR, was as previously described 
61
. Quality of extracted RNA 361 
was assessed using a Bioanalyzer 2100 (Agilent Technologies, Berkshire, UK) to ensure a minimum 362 
RIN of 8.0 for quantitative real time PCR (RT-qPCR) analyses of the in vitro samples and 7.0 for 363 
biopsy samples. Primers and annealing temperatures are presented in Table 1.  364 
Transfection of VK2 cells with TLR5 siRNA (s14199:ThermoFisher) was performed using Viromer 365 
Green (Lipocalyx) following the manufacturers protocol. The 48h knockdown was followed by a 24h 366 
flagellin challenge. 367 
 368 
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Bacterial Growth Measurements 369 
The immunosorbent experiments utilised urines collected from both flagellin and CFT073 challenged 370 
C57BL/6 wild-type mice. Urine samples were added to BD2 or Avian BD9 antibody (Cambridge 371 
Research Biochemicals, Cleveland, U.K.) coated ELISA plates (Leinco Technologies) and following a 372 
2h incubation the supernatants recovered and stored at -20 
o
C. Supernatants (100 µl/well) were used 373 
in bacterial growth experiments performed in 96 well microtitre plates and data analysed in relation to 374 
lag time extension 
63
. For bacterial growth, over-night cultures of CFT073 were inoculated into Luria 375 
broth, grown to mid-log phase (OD600=0.4), diluted to 10
4
 cells/ml and aliquoted into wells of 96-well 376 
microtitre plates containing control or biological samples.  The plates were incubated for 16 h in a 377 
Fluostar Omega plate reader set at 37ºC, shaken at 200rpm every 20 min and the bacterial OD600 378 
measured every 20 min.   379 
Human Beta-Defensin 2 (BD2) and Interleukin 8 (IL-8) Measurements  380 
Human BD2 was quantitated in clinical and cell culture samples using a Human BD2 ELISA 381 
Development Kit (Leinco Technologies, St Louis, Missouri, USA).   IL-8 concentrations were analysed 382 
using the BD optEIA IL-8 ELISA kit (BD Bioscience, Franklin Lakes, USA).   383 
Mice Experiments 384 
C57BL/6J wild-type and B6.129S1-Tlr5
tm/Flv
/J (Tlr5-/- knockout) female mice (obtained from Jackson 385 
Laboratories, Bar Harbor, ME.) were bred to between 6 and 8 weeks of age at the Duke University 386 
Medical Center animal care facility. E. coli CFT073 and E.coli flagellin were used for all murine 387 
infections. CFT073 cultures were inoculated from frozen stock into Luria broth [Becton Dickinson and 388 
Company (BD), Franklin Lakes, NJ] and grown overnight at 37°C. Optical density (OD) was 389 
determined and cultures were washed, and diluted in PBS. Bladder infections were performed as 390 
described previously 
6
. Essentially mice were anesthetized, catheterized with polyethylene tubing 391 
(inner diameter: 0.28 mm) (BD), and 50 ȝl  of PBS (control) or PBS containing either 108 bacteria or 5 392 
ȝg E.coli flagellin instilled from a 1 ml tuberculin syringe with a 30G1/2 needle. Mice were euthanized 393 
by CO2 asphyxiation and whole tissues (vaginas, bladders and kidneys) isolated for transcript 394 
analyses and bacterial CFU quantification.  All animal experiments were approved by the Duke 395 
University IACUC and Division of Laboratory Animal Resources, and performed in accordance with 396 
relevant guidelines and regulations.  397 
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Human Subjects  398 
The study was approved by the County Durham & Tees Valley 1 NHS Research Ethics Committee 399 
(09/H0905/15) and Newcastle upon Tyne Hospitals NHS Trust (ID 4841). Written informed consent 400 
was obtained from all participants and all methods were performed in accordance with relevant 401 
guidelines and regulations. Women with structurally-normal urinary tracts and consenting to provide 402 
biopsies, samples of blood, urine and vaginal washings were recruited from the Urology and Uro-403 
gynaecology departments of Newcastle upon Tyne Hospitals NHS Trust from July 2009 to February 404 
2011. Controls were recruited from women attending for investigation of haematuria or other non-405 
infection related uro-gynaecological assessment; rUTI sufferers were women who had suffered either 406 
at least two episodes per year for two years or three episodes in the previous year. Other inclusion 407 
criteria required subjects to be aged 18 years or older; pre-menopausal or at least six months 408 
postímenopause; no antibiotic therapy within four weeks of recruitment. Pre-investigation sample size 409 
calculations based on previous reported urinary AMP concentrations indicated that 18 women in each 410 
of the four groups (72 in total) would give 80% chance of detecting a difference at 5% significance 411 
level.  The women were stratified according to menopausal status to create four groups: 19 Pre-412 
menopausal controls (median age 35: range 18-46); 31 Pre-menopausal cases (rUTI sufferers) 413 
(median age 31: range 18-41) for which there were 26 complete analyses; 19 Post-menopausal 414 
controls (median age 58: range 42-76); 29 Post-menopausal cases (rUTI sufferers) (median age 60: 415 
range 40-75) for which there were 22 complete analyses. Clinical histories of rUTI and control 416 
subjects are presented in Table 2. 417 
Patient samples  418 
Biopsies from the first 2-3 cm of the vagina and posterior bladder wall were obtained during 419 
cystoscopy. Following cystoscopy, the first vaginal washing or douche was collected using the 420 
Summers Eve Cleansing Douche (Fleet Laboratories, Lynchburg, Virginia, USA) according to the 421 
manufacturers instructions.  Each subject was given the necessary instructions and containers to 422 
collect an overnight urine specimen (approximately 600-800ml) and a further vaginal douche 6-8 423 
weeks later. Preímenopausal subjects were requested to collect the douche at the midípoint of their 424 
menstrual cycle. Of the subjects that gave two douche samples, all were post-menopausal; nine were 425 
rUTI sufferers prescribed vaginal estrogen (Vagifem twice weekly 10mcg) and 12 were rUTI sufferers 426 
given treatments including antibiotic prophylaxis and/or advice (one did not complete). 427 
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Targeted TLR5 Sequencing  428 
Blood samples taken from each subject were processed for genomic DNA (gDNA) extraction using 429 
the GeneCatcher gDNA 310 mL Blood Kit (Invitrogen, Paisley, UK).  PCR amplification of the 430 
TLR5
392Stop
 containing region of the TLR5 gene was carried out on 100ng of gDNA using Novagen 431 
Kod Host start DNA Polymerase (Merck Millipore, Darmstadt, Germany) and the TLR5 Primer pair 432 
(forward primer, GGTAGCCTACATTGATTTGC; reverse primer, 433 
GAGAATCTGGAGATGAGGTACCCG).  A 10ȝL aliquot of the 461 bp product was used for 434 
sequencing (Genevision, Newcastle upon Tyne, UK).  Sequencing data was provided in AB1 format 435 
and data analyses performed using the freeware FinchTV trace viewing software (Geospiza, Seattle, 436 
USA).  437 
Immunohistochemistry  438 
Vaginal samples for immunohistochemistry were fixed in formalin overnight before being transferred 439 
to 70% ethanol for long term storage or paraffin embedding. Sections of 5-µm thickness were 440 
mounted on microscope slides and following microwave-heat mediated antigen retrieval were stained 441 
with anti-beta 2 Defensin primary antibody (Abcam, ab63982)1/1000 (1 X PBS), overnight at 4
o
C, 442 
followed by one hour at room temperature with polyclonal goat anti-rabbit Immunoglobulins/HRP 443 
1/3000 (DAKO). Images were taken using a Nikon Eclipse Ti, coupled to a Photometrics Coolsnap 444 
HQ CCD camera and Nikon Plan Fluor 100x/1.30 ph3 DL lens. 445 
 446 
Statistical Analyses  447 
All statistical analyses were performed out using the Prism 5 Software package (GraphPad Software 448 
Inc, La Jolla, California, USA). Significance of data with two groups was determined by unpaired two-449 
tailed Students t test; for more than two groups a twoway analyses of variance followed by Tukeys 450 
multiple comparison or Bonferroni post-tests, as appropriate, was used. For comparison of the first 451 
and second douche data, a paired two-tailed test was utilised. 452 
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Figure legends 
 
Figure 1: VK2 E6/E7 and RT4 DEFB4 and BD2 responses to UPEC and flagellin challenges. 
End point PCR panels of host defence peptide gene expression in VK2 E6/E7 and RT4 cells following 
24hr challenge with PBS (control), flagellin (250ng/ml) or UPEC (10
5
) (1a). Full length gels are shown 
in Supplementary File 1 (S1a-d). DEFB4 transcript expression in VK2 E6/E7 and RT4 cells following 
challenges with flagellin (250ng/ml) and heat-killed flagellated (NCTC10418) or non-flagellated 
(NU14) E.coli (105) (N=3, n=9) (1b). BD2 concentrations measured in VK2 E6/E7 and RT4 cell media 
following 24 hour challenges with flagellin (250ng/ml) and heat-killed CFT073 (10
5
) (N=3, n=6) (1c). 
BD2 peptide concentrations of primary ureteric urothelial cells challenged with E.coli flagellin 
(250ng/ml) for 24 hours (N=3, n=6) (1d). DEFB4 transcript expression, presented as relative 
expression, of primary vaginal epithelial cells challenged with E.coli flagellin (50ng/ml)  for 24 hours 
(N=6) (1e). E.coli swarming motility on LB agar media; BD2 peptide concentrations measured in VK2 
E6/E7 and RT4 cell media following 24 hour challenges with flagellin (250ng/ml) and heat-killed 
bacteria (10
5
) (N=3, n=6) (1f). DEFB4 transcript expression of VK2 E6/E7 cells transfected with either 
negative siRNA or TLR5 siRNA and challenged for 24 hours with flagellin (50ng/ml) (N=3) (1g). BD2 
peptide concentrations of VK2 E6/E7 cells incubated with TLR5 blocking antibody (1-5ug/ml) or IgG 
(5ug/ml) and challenged 24 hours with flagellin  (250ng/ml) (N=3) (1h). Fold change in NFƸB-
luciferase activity in RT4 cells challenged with 250ng/ml flagellin (FLG) for 2-8 hours, peptidoglycan 
(PG) (10µg/ml) for up to 16 hours and Lipopolysaccharide (LPS) (10µg/ml) for up to 16 hours (N=3, 
n=6 (FLG), n=9 (PG & LPS)) (1i). All data presented as mean ± SEM, * P<0.05, ** P<0.01, *** 
P<0.001. 
 
Figure 2: DefB4 expression in mouse urogenital tissues following UPEC and flagellin 
challenge 
DefB4 mRNA expression in wild type C57BL6 and Tlr5-/- mice bladders following 6h challenge with 
either flagellin (5µg) or CFT073 (10
8
) (N=3) (2a). Vaginal DefB4 mRNA expression in wild type 
C57BL6 and Tlr5-/- mice following 6h challenge with either flagellin (5µg) or CFT073 (108) (N=3) (2b). 
E. coli colonisation of the bladders and kidneys of wild type C57BL6 and Tlr5-/- mice following 6h 
CFT073 bladder challenge (N=3) (2c). All data presented as mean ± SEM, * P<0.05, ** P<0.01. 
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Figure 3: Effects of host defence peptides on CFT073 growth  
Time-kill data showing CFT073 survival following two hour incubation with host defence peptides BD2 
(30 and 300ng/ml: 7.5nM and 75nM), LCN2 (300 ng/ml: 13nm)) and SLPI (300 and 3000ng/ml: 25 
and 250nM) (N=4). Bacterial growth values >100% link to peptide concentrations not associated with 
bacterial killing suggesting amino acids associated with peptide degradation, either natural or 
bacterial protease activity, are used by the bacteria as a growth source (3a). CFT073 (10
4
) growth 
times in wild type mice urines depleted of DefB4 (controls: no depletion and Avian defensin antibody-
specific depletion) (3b). All data presented as mean ± SEM, * P<0.05, *** P<0.001. 
 
Figure 4: DEFB4 and TLR5 mRNA expression, and BD2 responses in control and rUTI patient 
samples 
DEFB4 mRNA expression, presented as relative expression (4a) and BD2 peptide concentrations 
(4b) in vaginal biopsies from control (N=38) and rUTI patients (N=48). Vaginal douche data stratified 
to show BD2 peptide concentrations of premenopausal (Pre-M) control subjects (N=19), 
premenopausal rUTI patients (N=26), postmenopausal (Post-M) control subjects (N=19) and 
postmenopausal rUTI patients (N=22) (4c). TLR5 mRNA expression, presented as relative 
expression, in vaginal biopsies from control subjects, patients with rUTI and rUTI at time of an active 
infection (4d). Urine BD2 concentrations of the rUTI No SNP (N=8) and TLR5
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 SNP patients 
(N=5) and vaginal douche BD2 peptide concentrations N=9 (No SNP) and N=5 (SNP) during periods 
of active infection (4e). Matched urine BD2 concentrations of rUTI non SNP (N=8) and TLR5
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SNP patients (N=5) analysed during periods of infection and non-infection (4f). Vaginal douche BD2 
peptide concentrations of no SNP rUTI patients measured during an acute infection alongside vaginal 
douche BD2 concentrations of the non-infected pre-menopausal control subjects (4g).  
NFƸB-luciferase activity (fold change) in RT4 cells following 2 to 24 hour challenges with heat killed 
UPEC (5x10
4
) isolated from the urines of three rUTI SNP patients during an acute infection (4h). 
NFƸB-luciferase activity (fold change) in RT4 cells incubated in presence or absence of TLR5 
blocking antibody (5ug/ml) or IgG (5ug/ml) following 24 hour challenge with flagellin (250ng/ml) or 
heat killed UPEC isolated from each of the three SNP patients (4i). IL-8 concentrations (pg/ml) in 
media of RT4 cells incubated in presence or absence of TLR5 blocking antibody (5ug/ml) and 
challenged for 24 hours with flagellin (250ng/ml) and bacteria isolated from each of the three SNP 
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patients (4j). BD2 concentrations (pg/ml) in media of RT4 bladder cells incubated in presence or 
absence of TLR5 blocking antibody (5ug/ml) and challenged for 24 hours with either flagellin 
(250ng/ml) or bacteria isolated from each of the three SNP patients (4k). N=2, n=6 and all data 
presented as mean ± SEM, * P<0.05, ** P<0.01, *** P<0.001.  
 
 Figure 5: Effects of estrogen treatment on BD2 responses in vitro and rUTI patients 
VK2 E6/E7 cell DEFB4 mRNA expression following estrogen (4nM) seven day pretreatment and 24h 
challenge with either cyclodextrin (15nM), flagellin (50ng/ml), or flagellin (50ng/ml) and estrogen 
(4nM) N=3 (5a). BD2 peptide concentrations measured in the VK2 E6/E7 cell media following 
estrogen (4nM) seven day pretreatment and either 24h or 48h challenge with either cyclodextrin 
(15nM), estrogen (4nM),  flagellin (50ng/ml) or flagellin and estrogen (N=3) (5b). Vaginal douche BD2 
peptide concentrations of rUTI patients before and after 6-8 weeks of treatment with antibiotic 
prophylaxis and/or advice (N=12) (5c), or 6 to 8 weeks treatment with vaginal estrogen (Vagifem, 
10mcg, twice weekly) (N=9) (5d). Staining of vaginal tissue from estrogen treated (+E) and control 
subjects for immunoreactive BD2 (5e). Vaginal douche BD2 peptide concentrations of rUTI TLR5 
SNP patients before and after treatment (6 to 8 weeks) with vaginal estrogen (N=3) or antibiotic 
prophylaxis (N=1) (5f). All data presented as mean ± SEM, ** P<0.01, *** P<0.001.  
 Schematic illustrating (i) how an inherited or acquired reduction in the vaginal host innate defences 
can facilitate an UPEC infection of the urogenital tract and (ii)  how vaginal treatments enhancing the 
host innate defences can help prevent this (5g). 1. Uropathogenic E.coli  (UPEC)          
originating from bowel migrate from rectum towards vagina; 2. Inherited or acquired reduction in 
innate defences including HDP and chemokines facilitates increased vaginal and peri-urethral 
colonisation by UPEC; 3. Urethral ascent of UPEC from peri-urethral and vaginal regions to bladder; 
4. Bladder infection; 5. Vaginal topical agent stimulates host innate defences and UPEC destroyed 
preventing vaginal colonisation; 6/7. Urethra and bladder protected from UPEC infection. 
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Table 1: Primer sequences  
 
Gene Primer Sequence Primer Type Tm (ºC) 
DEFB1 
Reverse: cgccGGTAGGAAGTTCTCATGGcG 
Forward: GTCAGCTCAGCCTCCAAAGGA 
Probes Master 60 
Defb4 
Forward: GTGAAGCTCCCAGCCATCAG 
Reverse: GATTGCGTATCTTTGGACACC 
SYBR Green I Master 58 
DEFB4 SA Biosciences commercial primer SYBR Green I Master 60 
DEFA5 
Forward: GCCATCCTTGCTGCCATTC 
Reverse: GATTTCACACACCCCGGAGA 
SYBR Green I Master 58 
hCAP-18 
Forward: cgctGACGGGCTGGTGAAGcG 
Reverse: CCCAGCAGGGCAAATCTCTT 
Probes Master 55 
TLR5 
Forward: CAGAGACTGGTGTTCAAGGAC 
Reverse: GTGTCCAGGTGTTTGAGCA 
SYBR Green I Master 54 
GAPDH 
Primer Design commercial primer 
(House-keeping reference gene) 
SYBR Green I Master 60 
ATP5B 
Primer Design commercial primer 
(House-keeping reference gene) 
SYBR Green I Master 60 
Mouse β-actin  Forward: TGAGAGGGAAATCGTGCGTGACAT 
Reverse: ACCGCTCATTGACGATAGTGATGA 
SYBR Green I Master 60 
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Table 2: Clinical History 
 
 
 
 Control rUTI 
Pre-menopause Post-menopause Pre-menopause Post-menopause 
Numbers Recruited  19 19 31 29 
Median Age (Range) 35 (18-46) 58 (42-76) 31 (18-41) 60(40-75)
Prescribed vaginal estrogen 
previously 
1 2 0 0  
Taking vitamins 4 3 4 4  
Taking cranberry-juice 5 5 16 15  
On oral contraception 6 0 4 0  
Had HRT 0 4 0 9  





